Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00496587
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
  • Gemcitabine — DRUG
    900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
  • Bevacizumab — DRUG
    10 mg/kg By Vein On Days 1 and 15.

Study Details

The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma. The safety of this drug combination will also be tested.

Key Dates

First listed
Jul 4, 2007
Start date
Jul 31, 2007
Status verified
Jun 2017
Primary completion
May 31, 2016
Completion
May 31, 2016

Study Design

Enrollment
34 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Capecitabine + Gemcitabine + Bevacizumab
    Capecitabine 800 mg/m\^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: 12 months or until progression of disease ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies